Friday, March 27, 2015

(Related update 2): Closer to a cure for Alzheimers?

Reminder: Due to illness, I am forced to modify my posting schedule ending, hopefully, by June 1st. Consequently, I am reducing the number of posts to two per day and will be relying on audio, video, and re-posts to a much greater extent than normal during this period.  Thank you for understanding and for continuing to visit – and recommending! -- On Liberty Street! Now on to the post:

Related update 2 :  And now comes this highly encouraging story about a new Biogen drug:
Biogen Idec's drug aducanumab has been shown to slow mental decline in patients with early or mild Alzheimer's disease in a small drug trial, the full results of which were released Friday. The New York Times reports 166 patients were randomly given low to high doses of the drug (meant to eliminate amyloid plaque in the brain) or a placebo. Experts say the trial was designed to assess aducanumab's safety rather than effects, but the drug proved to be the first to both ease plaque and slow cognitive decline, Forbes reports. "It would be kind of hard to get those kind of results by chance," a doctor says. Another adds the drug was "impressive" when taken in the highest dose. Over a year, placebo patients fell 3.14 points on a 30-point cognition scale, while those taking the highest dose dropped 0.58 points. Patients on a middle dose slid 0.75 points.
Click here to read more about this intriguing new development from the front line of cognitive functioning research.

Related update 1 (1/28/15): A recent Fox News story reports on the positive outcomes of a study at Wake Forest University involving a nasal spray and alzheimers disease:
Researchers say they’ve developed a nasal spray that could potentially improve memory and other mental capabilities for the more than 5 million Americans suffering from Alzheimer’s disease.
Participants who received 40 international unit (IU) doses of insulin detemir over the course of the trial showed significant improvement in their short-term ability to retain and process verbal and visual information, compared with those who received 20 IU doses or a placebo. According to Craft, performance on tests of mental manipulation and memory improved by as much as 25 percent.
Along with the original post below, this study suggests that researchers are starting to make serious inroads in dealing with this horrific disease that affects 5 million Americans.  Kudos to the researchers and scientists working in this area! [ht:]

Original post 8/17/13: Let's hope so....good news out of California: researchers at Stanford University's School of Medicine have identified a new protein thought to play a significant role in the deterioration of cognitive functioning in such diseases as Alzheimer's:
In a groundbreaking study from Stanford University School of Medicine, researchers detailed the significance of a protein called C1q, which was previously known as the initiator of the immune system response. After analyzing brain tissue in mice of varying ages, as well as postmortem samples of a 2-month-old infant and an elderly person, they discovered that C1q exponentially increases in the aging brain – creating as much as a 300-fold buildup. Comparatively, most age-associated increases of proteins in the brain are only three- or four-fold.
Much more information about this potentially huge breakthrough can be found here.  Ovations for the great researchers at Stanford University!